Legal & General Group
OVID icon

Legal & General Group’s Ovid Therapeutics OVID Stock Holding History

Legal & General Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40K Buy
+14,858
New +$38.3K ﹤0.01% 2850
2025
Q2 		– Sell
-6,579
Closed -$2.05K – 3504
2025
Q1 		$2.05K Hold
6,579
– – ﹤0.01% 3352
2024
Q4 		$6.14K Hold
6,579
– – ﹤0.01% 3325
2024
Q3 		$7.76K Hold
6,579
– – ﹤0.01% 3316
2024
Q2 		$5.06K Buy
6,579
+1,378
+26% +$3.83K ﹤0.01% 3377
2024
Q1 		$15.9K Hold
5,201
– – ﹤0.01% 3060
2023
Q4 		$16.7K Buy
5,201
+588
+13% +$2.01K ﹤0.01% 3102
2023
Q3 		$17.7K Sell
4,613
-1,150
-20% -$4.13K ﹤0.01% 3085
2023
Q2 		$18.9K Buy
+5,763
New +$19.6K ﹤0.01% 3130
2021
Q2 		– Sell
-5,199
Closed -$21K – 3605
2021
Q1 		$21K Sell
5,199
-21,322
-80% -$70.8K ﹤0.01% 3116
2020
Q4 		$61K Buy
26,521
+21,322
+410% +$99.4K ﹤0.01% 2746
2020
Q3 		$30K Sell
5,199
-1,863
-26% -$12.5K ﹤0.01% 2851
2020
Q2 		$52K Buy
+7,062
New +$33K ﹤0.01% 2718
2019
Q3 		– Sell
-2,145
Closed -$4K – 3398
2019
Q2 		$4K Hold
2,145
– – ﹤0.01% 3459
2019
Q1 		$4K Hold
2,145
– – ﹤0.01% 3321
2018
Q4 		$5K Hold
2,145
– – ﹤0.01% 3336
2018
Q3 		$12K Hold
2,145
– – ﹤0.01% 3302
2018
Q2 		$17K Hold
2,145
– – ﹤0.01% 3227
2018
Q1 		$15K Buy
2,145
+1,047
+95% +$8.47K ﹤0.01% 3162
2017
Q4 		$11K Hold
1,098
– – ﹤0.01% 3227
2017
Q3 		$10K Hold
1,098
– – ﹤0.01% 3278
2017
Q2 		$11K Buy
+1,098
New +$14.3K ﹤0.01% 3307

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Legal & General Group's OVID Position: Q2 2026 in Review

Legal & General Group opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 14,858 shares worth $40K. The stake represents ﹤0.01% of the portfolio and ranks #2850 among its holdings. This is a return to the name: Legal & General Group previously reported a position in OVID as recently as Q1 2025.

Legal & General Group first reported a position in OVID in Q2 2017 and has held it in 22 quarters since. The position peaked at $61K in Q4 2020. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Legal & General Group held 14,858 shares of Ovid Therapeutics worth $40K as of Q2 2026.
  • Ovid Therapeutics was a new Legal & General Group position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2850 holding.
  • Legal & General Group first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 22 quarters since.
  • Legal & General Group's Ovid Therapeutics position peaked at $61K in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.